Paravertebral Block for Percutaneous Nephrolithotomy (PRONE)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2015 by Loyola University
Information provided by (Responsible Party):
Elizabeth Mueller, Loyola University Identifier:
First received: November 23, 2011
Last updated: August 10, 2015
Last verified: August 2015
This study will compare post-operative pain levels in patients who receive paravertebral block prior to Percutaneous Nephrolithotomy (PCNL) surgery versus those who do not receive the block. We hypothesize that patients who receive the block will have lower post-operative pain scores and require less narcotics.

Condition Intervention
Post Operative Pain
Drug: Group A-Paravertebral block
Other: Group B- No block

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Paravertebral Block for Percutaneous Nephrolithotomy (PRONE)

Further study details as provided by Loyola University:

Primary Outcome Measures:
  • Pain Score [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
    post-operative pain will be measured by the Visual Analog Scale (VAS.

Secondary Outcome Measures:
  • Opiod Use [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
    All patients will receive the same post-operative pain control, which does not deviate from our standard protocol for patients receiving PCNL. All patients will be immediately given a PCA in recovery. Patients allergic to morphine/dilaudid will be given a narcoticopioid substitute (that will be converted to morphine equivalents for the purpose of the study). Nurses will be allowed to administer IV boluses of morphine PRN for inadequate pain control. If four boluses did not yield adequate analgesia, fentayl 50mcg will be used until adequate pain control is achieved.

Estimated Enrollment: 82
Study Start Date: August 2011
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Group B- No Block
Participants randodmized to this arm will have a local anesthetic injection and pressure applied to the paravertebral space. A paravertebral injection will not be conducted.
Other: Group B- No block
direct pressure for 5 minutes will be held at the site of the where the local anesthetic was applied to mimic the application of the block.
Other Name: Placebo Group
Active Comparator: Group A- Paravertebral block
Participants randodmized to this arm will have a local anesthetic (Bupivicaine 0.5% without epinephrine) injection and will be given a paravetebral block into the T10 paravertebral space..
Drug: Group A-Paravertebral block
Bupivicaine 0.5% without epinephrine (100mg)20cc will be injected into the T10 paravertebral space. Active Group
Other Name: Group A-Paravertebral block Active Group

Detailed Description:

The strategies used to manage nephrolithiasis including medical expulsive therapy, extracorporeal shock wave (ESWL), ureteroscopy, open surgery and percutaneous nephrolithotomy (PCNL). PCNL in an inpatient procedure performed in two steps. Step 1, is the placement of a drainage line (nephrostomy tube) from the back into the collecting system of the kidney. This step is typically performed by interventional radiologists under conscious sedation. Step 2 is performed by urologists and involves dilating the tract of the nephrostomy tube, placement of an access sheath and actual removal of the stone using endoscopic equipment. The minimally invasive approach of PCNL is well accepted to be as effective as open procedures for stone removal with less morbidity. Post-operative pain management remains challenging and can lead to extended hospital stays.

This randomized, double-blinded trial designed to assess the effects of paravertebral block on intra-operative and post-operative pain control.


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Consent to undergo percutaneous nephrolithotomy
  • Between the ages of 18 and 75
  • Able to consent, fill out study documents, and complete all study procedures and follow-up visits

Exclusion Criteria:

  • Will have bilateral percutaneous nephrolithotomy
  • Have an infection at the site of the proposed block
  • Have anatomy that prevents ability to perform block
  • Have a coagulopathy which may increase their chances of bleeding from the block
  • Have a known allergy to local anesthetics
  • Are unable to fill out the VAS scale due to physical or mental conditions
  • Are unable to use a patient controlled analgesia (PCA) device due to physical or mental conditions
  • Are pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01480102

Contact: Elizabeth Mueller, MD 708-216-2180

United States, Illinois
Loyola University Medical Center Recruiting
Maywood, Illinois, United States, 60153
Contact: Elizabeth Mueller, MD    708-216-2180   
Sponsors and Collaborators
Loyola University
Principal Investigator: Elizabeth Mueller, MD Loyola University
  More Information

No publications provided

Responsible Party: Elizabeth Mueller, Associate Professor, Loyola University Identifier: NCT01480102     History of Changes
Other Study ID Numbers: 203648 
Study First Received: November 23, 2011
Last Updated: August 10, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Loyola University:
Percutaneous nephrolithotomy
Paravertebral block

Additional relevant MeSH terms:
Pain, Postoperative
Pathologic Processes
Postoperative Complications
Signs and Symptoms
Anesthetics, Local
Central Nervous System Agents
Central Nervous System Depressants
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on February 11, 2016